Section Arrow
KYMR.NASDAQ
- Kymera Therapeutics
Quotes are at least 15-min delayed:2026/09/01 07:59 EDT
Pre Market
Last
 118.49
-0.32 (-0.27%)
Bid
117
Ask
133.37
High 121.99 
Low 117.01 
Volume 926 
Regular Hours (Closed)
Last
 118.81
+0.66 (+0.56%)
Day High 
119.93 
Prev. Close
118.15 
1-M High
127.85 
Volume 
656.83K 
Bid
117
Ask
133.37
Day Low
115.97 
Open
118.6 
1-M Low
99.52 
Market Cap 
9.82B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 122.3 
20-SMA 115.56 
50-SMA 112.32 
52-W High 130.05 
52-W Low 39.84 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.25/-4.95
Enterprise Value
9.89B
Balance Sheet
Book Value Per Share
18.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
39.21M
Operating Revenue Per Share
0.56
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
Pre Market 0.3125 -0.0754 -19.44%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
Pre Market 0.2388 +0.0128 +5.66%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
Pre Market 34.12 -0.52 -1.50%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
Pre Market 1.47 -0.28 -16.00%
MRNAModerna140.34+2.35+1.70%-- 
Pre Market 137.61 -2.73 -1.95%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.